RT Journal Article
T1 The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose‐intensive chemotherapy including rituximab
A1 Forero‐Castro, Maribel
A1 Robledo, Cristina
A1 Lumbreras, Eva
A1 Benito, Rocio
A1 Hernández‐Sánchez, Jesús M.
A1 Hernández Sánchez, María
A1 García, Juan L.
A1 Corchete‐Sánchez, Luis A.
A1 Tormo, Mar
A1 Barba, Pere
A1 Menárguez Palanca, Francisco Javier
A1 Ribera, Jordi
A1 Grande, Carlos
A1 Escoda, Lourdes
A1 Olivier, Carmen
A1 Carrillo, Estrella
A1 García de Coca, Alfonso
A1 Ribera, Josep‐María
A1 Hernández‐Rivas, Jesús M.
AB The introduction of Rituximab has improved the outcome and survivalrates of Burkitt lymphoma (BL). However, early relapse and refractorinessare current limitations of BL treatment and new biological factors affectingthe outcome of these patients have not been explored. This study aimed toidentify the presence of genomic changes that could predict the response tonew therapies in BL. Forty adolescent and adult BL patients treated withthe Dose-Intensive Chemotherapy Including Rituximab (Burkimab) proto-col (Spanish Programme for the Study and Treatment of HaematologicalMalignancies; PETHEMA) were analysed using array-based comparativegenomic hybridization (CGH). In addition, the presence ofTP53, TCF3(E2A),  ID3andGNA13mutations  was  assessed  by  next-generationsequencing (NGS). Ninety-seven per cent of the patients harboured geno-mic imbalances. Losses on 11q, 13q, 15q or 17p were associated with apoor response to Burkimab therapy (P=0 038), shorter progression-freesurvival (PFS;P=0 007) and overall survival (OS;P=0 009). The integra-tive analysis of array-CGH and NGS showed that 26 3% (5/19) and 36 8%(7/19) of patients carried alterations in theTP53andTCF3genes, respec-tively.TP53alterations were associated with shorter PFS (P=0 011) whileTCF3alterations were associated with shorter OS (P=0 032). Geneticstudies could be used for risk stratification of BL patients treated with theBurkimab protocol.
PB John Wiley & Sons Ltd
SN 0007-1048
YR 2016
FD 2016-01-28
LK https://hdl.handle.net/20.500.14352/93287
UL https://hdl.handle.net/20.500.14352/93287
LA eng
NO Forero‐Castro M, Robledo C, Lumbreras E, Benito R, Hernández‐Sánchez JM, Hernández‐Sánchez M, et al. The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose‐intensive chemotherapy including rituximab. Br J Haematol 2016;172:428–38. https://doi.org/10.1111/bjh.13849.
NO European Union’s Seventh Framework Programme
NO Fundación Castellano-Leonesa de Hematología y Hemoterapia
NO Consejería de Educación, Junta de Castilla y León
NO Fondo de Investigaciones Sanitarias
NO Red Temática de Investigación Cooperativa en Cáncer
NO Instituto de Salud Carlos III
NO Spanish Ministry of Economy and Competitiveness and the European Regional Development Fund
NO IRON-II collaborative network of haematological laboratories
NO Junta de Castilla y León
NO UPTC, Colombia
DS Docta Complutense
RD 10 abr 2025